Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease

What Was Tested

Researchers studied Somatostatin in this controlled clinical trial publication.

To evaluate its clinical usefulness in Graves' disease, (99m)Tc-P829 scintigraphy (approximately equal to 740 MBq) was performed in 44 patients with TAO (median duration, 19 mo; range, 1-360 mo).

Why It Was Studied

Receptors for somatostatin (SST) (SSTR) are expressed on various tumor cells as well as on activated lymphocytes.

Consequently, (99m)Tc-P829 was successfully introduced as a peptide tracer for tumor imaging.

Who Took Part

The study group was 44 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

Orbital uptake ratios in Graves' disease were compared with data obtained from lung cancer patients with no eye disease (n = 22).

How the Study Was Run

SPECT (360 degrees ) and planar studies were completed within 3 h after injection.

Orbital (O) regions of interest (ROIs) were compared with temporoparietal and occipital (OCC) ROIs.

What Was Measured

In this study, the researchers evaluated the orbital uptake of (99m)Tc-P829 in patients with active and inactive thyroid-associated orbitopathy (TAO), accompanied by lymphocyte infiltration in the acute stage and by muscle fibrosis in the chronic stage of the disease.

PubMed files the paper under topics including Cornea, Graves Disease, Lung Neoplasms, Oculomotor Muscles, Orbit, Organotechnetium Compounds and Peptides, Cyclic.

What This Means in Plain Language

This is a controlled clinical trial of Somatostatin in 44 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Somatostatin compound page, all human trials.